NAMS Menopause Certification Comprehensive
Board Review Updated 2026 | 350+ Practice
Questions & Verified Answers | Ultimate
Menopause Society Certification Study Guide,
Women's Health Exam Prep, Hormone Therapy,
Perimenopause, Postmenopause, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Osteoporosis Prevention, Cardiovascular
Health, Evidence-Based Clinical Guidelines,
Detailed Rationales
Question 1: A 52-year-old woman in the menopause transition reports heavy,
prolonged menstrual bleeding occurring every 21 days. Which of the following
is the MOST appropriate first-line pharmacologic intervention to reduce acute
blood loss while preserving fertility?
A. Oral conjugated equine estrogens
B. Medroxyprogesterone acetate 10 mg daily for 14 days
C. Tranexamic acid 1300 mg three times daily during menses
D. Leuprolide acetate depot injection
CORRECT ANSWER: C. Tranexamic acid 1300 mg three times daily during
menses
Rationale: Tranexamic acid is an antifibrinolytic that directly reduces menstrual blood
loss by inhibiting plasminogen activation. It is a first-line, non-hormonal option for acute
heavy menstrual bleeding in perimenopausal women who desire fertility preservation or
are not candidates for hormonal therapy. Oral progestins are used for cycle regulation,
but their efficacy for acute volume reduction is less direct. Leuprolide is reserved for
severe cases or pre-surgical management, and estrogen alone is inappropriate without
progestin in a woman with an intact uterus.
Question 2: Which of the following changes in gonadotropin levels is
CHARACTERISTIC of the late menopausal transition (Stage -1) according to
the STRAW +10 criteria?
A. Elevated FSH with low estradiol and normal LH
B. Elevated LH with low FSH and low inhibin B
C. Low FSH and low LH with low estradiol
D. Elevated FSH and LH with elevated estradiol
CORRECT ANSWER: A. Elevated FSH with low estradiol and normal LH
Rationale: In the late menopausal transition, follicle depletion leads to a dramatic rise in
FSH due to decreased inhibin B and estradiol negative feedback, while LH remains
normal or only slightly elevated. This FSH predominance is a hallmark of ovarian aging.
Option B is incorrect as LH is not typically elevated more than FSH. Option C describes
,hypothalamic amenorrhea. Option D is inconsistent with the estrogen decline typical of
this stage.
Question 3: A postmenopausal woman is diagnosed with vulvovaginal atrophy
(VVA). She has a history of breast cancer treated with an aromatase inhibitor.
What is the SAFEST treatment option for her genitourinary symptoms?
A. Systemic hormone therapy with estradiol patch
B. Vaginal estrogen cream 0.5 g twice weekly
C. Vaginal moisturizers and lubricants
D. Oral ospemifene 60 mg daily
CORRECT ANSWER: C. Vaginal moisturizers and lubricants
Rationale: In breast cancer survivors on aromatase inhibitors, systemic and even
localized vaginal estrogen therapy is generally contraindicated due to the risk of
systemic absorption and stimulation of hormone-sensitive tissue. Non-hormonal vaginal
moisturizers and lubricants are the safest and preferred first-line approach. Ospemifene
is a SERM used for dyspareunia but is not recommended in this population due to
thrombotic risks and lack of safety data with aromatase inhibitors.
Question 4: Which of the following is a PRIMARY mechanism by which
menopausal hormone therapy (MHT) reduces the risk of osteoporotic
fractures?
A. Stimulation of osteoclast activity and bone resorption
B. Direct inhibition of parathyroid hormone secretion
C. Suppression of osteoblast apoptosis and increased collagen synthesis
D. Inhibition of RANKL-mediated osteoclastogenesis
CORRECT ANSWER: D. Inhibition of RANKL-mediated osteoclastogenesis
Rationale: Estrogen inhibits the production of RANKL (receptor activator of nuclear
factor kappa-B ligand) by osteoblasts and stromal cells. This reduces osteoclast
differentiation and survival, thereby decreasing bone resorption. While estrogen does
affect osteoblast function, the primary anti-fracture effect is mediated through
suppression of bone turnover and reduction of osteoclast activity.
Question 5: A 48-year-old woman with a history of migraine with aura
requests initiation of MHT for severe vasomotor symptoms. Which
formulation is CONTRAINDICATED due to stroke risk?
A. Transdermal estradiol patch
B. Oral conjugated equine estrogens 0.625 mg
C. Micronized progesterone 100 mg
D. Vaginal estradiol ring
CORRECT ANSWER: B. Oral conjugated equine estrogens 0.625 mg
,Rationale: Oral estrogen undergoes first-pass hepatic metabolism, leading to increased
production of coagulation factors and a higher risk of venous thromboembolism (VTE)
and stroke. This risk is amplified in women with migraine with aura. Transdermal
estradiol avoids first-pass metabolism and is considered safer in women with a history of
migraine with aura. Progesterone and vaginal rings are not contraindicated in this
context.
Question 6: A 55-year-old woman presents with insomnia, hot flashes, and
mood swings. She has a BMI of 34 and a history of hypertension. Which MHT
regimen provides the LOWEST risk of venous thromboembolism (VTE)?
A. Oral estradiol 1 mg and norethindrone 0.5 mg
B. Transdermal estradiol 50 mcg/day with micronized progesterone
C. Oral conjugated equine estrogens 0.3 mg daily alone
D. Estradiol vaginal cream 0.1 mg twice weekly
CORRECT ANSWER: B. Transdermal estradiol 50 mcg/day with micronized
progesterone
Rationale: Transdermal estrogen bypasses the hepatic first-pass effect, resulting in a
significantly lower risk of VTE compared to oral formulations. Micronized progesterone
(rather than synthetic progestins) is associated with a neutral or reduced thrombotic
risk. This makes the combination in option B the safest choice for an obese,
hypertensive patient. Option D lacks efficacy for systemic vasomotor symptoms.
Question 7: Which of the following biochemical findings is MOST consistent
with primary ovarian insufficiency (POI) in a 35-year-old woman?
A. FSH 55 IU/L, estradiol <20 pg/mL
B. FSH 10 IU/L, estradiol 60 pg/mL
C. LH 40 IU/L, FSH 15 IU/L
D. FSH 5 IU/L, estradiol 200 pg/mL
CORRECT ANSWER: A. FSH 55 IU/L, estradiol <20 pg/mL
Rationale: Primary ovarian insufficiency is defined by elevated gonadotropins (FSH >
25 IU/L on two occasions) and low estradiol levels in a woman under 40. Option A is
the only one demonstrating this classic pattern. Option B shows normal FSH and
estradiol, and Option C is incorrect due to the low FSH relative to LH. Option D is
consistent with a normal or follicular phase.
Question 8: During the menopause transition, which change in the menstrual
cycle is MOST predictive of the final menstrual period (FMP)?
A. Alternating short and long cycles
B. A persistent increase in cycle length of 7 days or more
C. An increase in menstrual flow duration exceeding 10 days
D. Intermenstrual spotting for six months
CORRECT ANSWER: B. A persistent increase in cycle length of 7 days or more
, Rationale: The STRAW +10 staging system identifies a persistent variability in cycle
length of 7 days or more (Stage -1) as highly predictive of the FMP. This change reflects
the transition from early perimenopause (Stage -2, shorter cycles) to late
perimenopause. While flow changes and spotting occur, the hallmark clinical marker is a
significant lengthening of the intermenstrual interval.
Question 9: A 53-year-old woman on continuous combined MHT (estradiol +
norethindrone) reports unscheduled vaginal bleeding after 18 months of
amenorrhea. Which of the following is the MOST appropriate next step?
A. Reassurance and observation for 3 months
B. Increase progestin dose to stop breakthrough bleeding
C. Transvaginal ultrasound to measure endometrial thickness
D. Change to a cyclic progestin regimen
CORRECT ANSWER: C. Transvaginal ultrasound to measure endometrial
thickness
Rationale: Unscheduled bleeding on continuous combined MHT after 12 months of use
requires evaluation. A transvaginal ultrasound is the recommended first-line
investigation to assess endometrial stripe thickness. An endometrial thickness of < 4-5
mm in a patient on MHT is considered reassuring and may preclude invasive
procedures. Endometrial biopsy is indicated if thickness exceeds 5 mm or bleeding
persists.
Question 10: Which of the following is considered a MAJOR criterion for
diagnosing genitourinary syndrome of menopause (GSM)?
A. Recurrent urinary tract infections
B. A vaginal pH of ≤ 5.0
C. Presence of lactobacilli on wet mount
D. Maturation index showing > 50% superficial cells
CORRECT ANSWER: A. Recurrent urinary tract infections
Rationale: GSM encompasses both vulvovaginal and lower urinary tract symptoms.
Recurrent UTIs are a major diagnostic criterion due to the loss of vaginal lactobacilli,
increased pH, and altered microbiome. A low pH and presence of lactobacilli are signs
of estrogenization, not deficiency. A maturation index showing mostly superficial cells
indicates an estrogenized state.
Question 11: A 60-year-old woman with osteoporosis is considering MHT
solely for fracture prevention. She has not had a menstrual period for 12 years.
Which statement about the "timing hypothesis" is MOST accurate regarding
her initiation of MHT?
A. Benefits of MHT on cardiovascular health are greatest when started within 10 years
of menopause
B. Risks of MHT are lower in this patient regardless of cardiovascular status
Board Review Updated 2026 | 350+ Practice
Questions & Verified Answers | Ultimate
Menopause Society Certification Study Guide,
Women's Health Exam Prep, Hormone Therapy,
Perimenopause, Postmenopause, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Osteoporosis Prevention, Cardiovascular
Health, Evidence-Based Clinical Guidelines,
Detailed Rationales
Question 1: A 52-year-old woman in the menopause transition reports heavy,
prolonged menstrual bleeding occurring every 21 days. Which of the following
is the MOST appropriate first-line pharmacologic intervention to reduce acute
blood loss while preserving fertility?
A. Oral conjugated equine estrogens
B. Medroxyprogesterone acetate 10 mg daily for 14 days
C. Tranexamic acid 1300 mg three times daily during menses
D. Leuprolide acetate depot injection
CORRECT ANSWER: C. Tranexamic acid 1300 mg three times daily during
menses
Rationale: Tranexamic acid is an antifibrinolytic that directly reduces menstrual blood
loss by inhibiting plasminogen activation. It is a first-line, non-hormonal option for acute
heavy menstrual bleeding in perimenopausal women who desire fertility preservation or
are not candidates for hormonal therapy. Oral progestins are used for cycle regulation,
but their efficacy for acute volume reduction is less direct. Leuprolide is reserved for
severe cases or pre-surgical management, and estrogen alone is inappropriate without
progestin in a woman with an intact uterus.
Question 2: Which of the following changes in gonadotropin levels is
CHARACTERISTIC of the late menopausal transition (Stage -1) according to
the STRAW +10 criteria?
A. Elevated FSH with low estradiol and normal LH
B. Elevated LH with low FSH and low inhibin B
C. Low FSH and low LH with low estradiol
D. Elevated FSH and LH with elevated estradiol
CORRECT ANSWER: A. Elevated FSH with low estradiol and normal LH
Rationale: In the late menopausal transition, follicle depletion leads to a dramatic rise in
FSH due to decreased inhibin B and estradiol negative feedback, while LH remains
normal or only slightly elevated. This FSH predominance is a hallmark of ovarian aging.
Option B is incorrect as LH is not typically elevated more than FSH. Option C describes
,hypothalamic amenorrhea. Option D is inconsistent with the estrogen decline typical of
this stage.
Question 3: A postmenopausal woman is diagnosed with vulvovaginal atrophy
(VVA). She has a history of breast cancer treated with an aromatase inhibitor.
What is the SAFEST treatment option for her genitourinary symptoms?
A. Systemic hormone therapy with estradiol patch
B. Vaginal estrogen cream 0.5 g twice weekly
C. Vaginal moisturizers and lubricants
D. Oral ospemifene 60 mg daily
CORRECT ANSWER: C. Vaginal moisturizers and lubricants
Rationale: In breast cancer survivors on aromatase inhibitors, systemic and even
localized vaginal estrogen therapy is generally contraindicated due to the risk of
systemic absorption and stimulation of hormone-sensitive tissue. Non-hormonal vaginal
moisturizers and lubricants are the safest and preferred first-line approach. Ospemifene
is a SERM used for dyspareunia but is not recommended in this population due to
thrombotic risks and lack of safety data with aromatase inhibitors.
Question 4: Which of the following is a PRIMARY mechanism by which
menopausal hormone therapy (MHT) reduces the risk of osteoporotic
fractures?
A. Stimulation of osteoclast activity and bone resorption
B. Direct inhibition of parathyroid hormone secretion
C. Suppression of osteoblast apoptosis and increased collagen synthesis
D. Inhibition of RANKL-mediated osteoclastogenesis
CORRECT ANSWER: D. Inhibition of RANKL-mediated osteoclastogenesis
Rationale: Estrogen inhibits the production of RANKL (receptor activator of nuclear
factor kappa-B ligand) by osteoblasts and stromal cells. This reduces osteoclast
differentiation and survival, thereby decreasing bone resorption. While estrogen does
affect osteoblast function, the primary anti-fracture effect is mediated through
suppression of bone turnover and reduction of osteoclast activity.
Question 5: A 48-year-old woman with a history of migraine with aura
requests initiation of MHT for severe vasomotor symptoms. Which
formulation is CONTRAINDICATED due to stroke risk?
A. Transdermal estradiol patch
B. Oral conjugated equine estrogens 0.625 mg
C. Micronized progesterone 100 mg
D. Vaginal estradiol ring
CORRECT ANSWER: B. Oral conjugated equine estrogens 0.625 mg
,Rationale: Oral estrogen undergoes first-pass hepatic metabolism, leading to increased
production of coagulation factors and a higher risk of venous thromboembolism (VTE)
and stroke. This risk is amplified in women with migraine with aura. Transdermal
estradiol avoids first-pass metabolism and is considered safer in women with a history of
migraine with aura. Progesterone and vaginal rings are not contraindicated in this
context.
Question 6: A 55-year-old woman presents with insomnia, hot flashes, and
mood swings. She has a BMI of 34 and a history of hypertension. Which MHT
regimen provides the LOWEST risk of venous thromboembolism (VTE)?
A. Oral estradiol 1 mg and norethindrone 0.5 mg
B. Transdermal estradiol 50 mcg/day with micronized progesterone
C. Oral conjugated equine estrogens 0.3 mg daily alone
D. Estradiol vaginal cream 0.1 mg twice weekly
CORRECT ANSWER: B. Transdermal estradiol 50 mcg/day with micronized
progesterone
Rationale: Transdermal estrogen bypasses the hepatic first-pass effect, resulting in a
significantly lower risk of VTE compared to oral formulations. Micronized progesterone
(rather than synthetic progestins) is associated with a neutral or reduced thrombotic
risk. This makes the combination in option B the safest choice for an obese,
hypertensive patient. Option D lacks efficacy for systemic vasomotor symptoms.
Question 7: Which of the following biochemical findings is MOST consistent
with primary ovarian insufficiency (POI) in a 35-year-old woman?
A. FSH 55 IU/L, estradiol <20 pg/mL
B. FSH 10 IU/L, estradiol 60 pg/mL
C. LH 40 IU/L, FSH 15 IU/L
D. FSH 5 IU/L, estradiol 200 pg/mL
CORRECT ANSWER: A. FSH 55 IU/L, estradiol <20 pg/mL
Rationale: Primary ovarian insufficiency is defined by elevated gonadotropins (FSH >
25 IU/L on two occasions) and low estradiol levels in a woman under 40. Option A is
the only one demonstrating this classic pattern. Option B shows normal FSH and
estradiol, and Option C is incorrect due to the low FSH relative to LH. Option D is
consistent with a normal or follicular phase.
Question 8: During the menopause transition, which change in the menstrual
cycle is MOST predictive of the final menstrual period (FMP)?
A. Alternating short and long cycles
B. A persistent increase in cycle length of 7 days or more
C. An increase in menstrual flow duration exceeding 10 days
D. Intermenstrual spotting for six months
CORRECT ANSWER: B. A persistent increase in cycle length of 7 days or more
, Rationale: The STRAW +10 staging system identifies a persistent variability in cycle
length of 7 days or more (Stage -1) as highly predictive of the FMP. This change reflects
the transition from early perimenopause (Stage -2, shorter cycles) to late
perimenopause. While flow changes and spotting occur, the hallmark clinical marker is a
significant lengthening of the intermenstrual interval.
Question 9: A 53-year-old woman on continuous combined MHT (estradiol +
norethindrone) reports unscheduled vaginal bleeding after 18 months of
amenorrhea. Which of the following is the MOST appropriate next step?
A. Reassurance and observation for 3 months
B. Increase progestin dose to stop breakthrough bleeding
C. Transvaginal ultrasound to measure endometrial thickness
D. Change to a cyclic progestin regimen
CORRECT ANSWER: C. Transvaginal ultrasound to measure endometrial
thickness
Rationale: Unscheduled bleeding on continuous combined MHT after 12 months of use
requires evaluation. A transvaginal ultrasound is the recommended first-line
investigation to assess endometrial stripe thickness. An endometrial thickness of < 4-5
mm in a patient on MHT is considered reassuring and may preclude invasive
procedures. Endometrial biopsy is indicated if thickness exceeds 5 mm or bleeding
persists.
Question 10: Which of the following is considered a MAJOR criterion for
diagnosing genitourinary syndrome of menopause (GSM)?
A. Recurrent urinary tract infections
B. A vaginal pH of ≤ 5.0
C. Presence of lactobacilli on wet mount
D. Maturation index showing > 50% superficial cells
CORRECT ANSWER: A. Recurrent urinary tract infections
Rationale: GSM encompasses both vulvovaginal and lower urinary tract symptoms.
Recurrent UTIs are a major diagnostic criterion due to the loss of vaginal lactobacilli,
increased pH, and altered microbiome. A low pH and presence of lactobacilli are signs
of estrogenization, not deficiency. A maturation index showing mostly superficial cells
indicates an estrogenized state.
Question 11: A 60-year-old woman with osteoporosis is considering MHT
solely for fracture prevention. She has not had a menstrual period for 12 years.
Which statement about the "timing hypothesis" is MOST accurate regarding
her initiation of MHT?
A. Benefits of MHT on cardiovascular health are greatest when started within 10 years
of menopause
B. Risks of MHT are lower in this patient regardless of cardiovascular status
